COCH

Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.32 per share a year ago.

Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives. "The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market," said Brent Lucas, Chief Executive Officer of Envoy Medical.

Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build momentum with the hearing industry.

Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement.

Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product. The submission marks the first regulatory milestone in the Company's planned modular PMA strategy.

Termination Reflects Company's Confidence in Current Capital Position White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility"). The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its common stock from time to time, has been terminated effective June 24, 2026.

White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum Dates: June 24th & 25th Presentation Day and Time: Thursday, June 25, 2026, at 1:00 p.m.

White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas, NV Booth: #410 Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M.

Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry. "As we continue advancing fully implanted hearing technology, protecting the innovation behind these systems remains a key priority for Envoy Medical," said Brent Lucas, CEO, Envoy Medical.